

ForPatients

by Roche

Lupus Nephritis

## A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

**Trial Status**  
Completed

**Trial Runs In**  
11 Countries

**Trial Identifier**  
NCT02550652 2015-002022-39  
WA29748

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02550652 2015-002022-39 WA29748**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 75 Years

**Healthy Volunteers**  
No

---